The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

Former Arizona Cardinals kicker Jay Feely announced his candidacy to replace Republican Congressman Andy Biggs, who is ...

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that March ...

CD5 CAR-T cells were successfully manufactured for 93% of attempted production runs. Importantly, the therapy showed a manageable safety profile with no grade 3 or higher cytokine release syndrome ...

The trial will test MB-105 in up to 46 patients with relapsed or refractory CD5-positive cutaneous T-cell lymphoma or peripheral T-cell lymphoma.

VIPER-101 is built on Vittoria’s proprietary Senza5™ platform, which integrates CD5 gene-editing technology with a rapid five-day manufacturing process. This platform is designed to enhance ...

a first-in-class CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Chronic lymphocytic leukemia (CLL) cell–derived exosomes demonstrated the ability to alter healthy donor cell function and ...

Novel CAR design selectively targets malignant cells for patients with relapsed/refractory CD5-positive hematological diseases HOUSTON, April 22, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio) ...

Biosciences announced the first patient has been dosed in its Phase 2 trial of MB-105, a first-in-class CD5-targeted CAR-T ...